Nottingham patients to benefit from new NHS Partnership

Patients in Nottingham are set to benefit from £1.5million of funding announced today by the Health and Social Care Secretary to trial innovative technology that could help deliver an improved breast screening service to women across the UK in the years to come.

Nottingham University Hospitals  NHS Trust (NUH), the host of East Midlands Radiology Consortium (EMRAD), has launched an 18 month project using Artificial Intelligence (AI) to support breast screening as one of  seven new NHS Test Beds.

Andrew Fearn, EMRAD Accountable Officer, and Director of Digital Services at NUH: “We are very excited about Office for Life Sciences and NHS England backing us to improve the quality of care and reduce the instance of breast cancer for women in the East Midlands. We genuinely believe that the lives of patients will be saved as a result of this project which supports breast screening services through the use of Artificial Intelligence.”

EMRAD is an established collaboration of seven NHS acute Trusts in the East Midlands. The project aims to screen and treat more people to support service capacity, boost patient, public and clinical confidence in using AI technology and to improve patient care.

To achieve these aims EMRAD have entered into Wave 2 of the Test bed programme with the following partners:

  • GE Healthcare – a long standing technical partner already supporting the EMRAD consortium.
  • Kheiron Medical Technologies and ASI Data Science - two UK based Small Medium Enterprises specialising in the field of cutting artificial intelligence technologies.
  • East Midlands Academic Health Science Network - helping us to scale and spread our work throughout the NHS.
  • Optimity Advisors - Local evaluation partners ensuring that the project clearly defines success criteria and monitors progress against this.

The AI tool will specifically help radiologists deliver more accurate and consistent results and reduce the need for recalls and biopsies. This is estimated to deliver an improved service to 170,000 women within the East Midlands and up to 2.2million annually in the UK by 2021.

EMRAD is one of seven test beds, from Wave 2 of the test bed programme. The test bed programme aims to tackle some of the biggest health care challenges by testing new digital technologies and using the potential of innovations to transform the way healthcare is delivered.